Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.

You may also be interested in...



Spectrum Licenses Third-Generation Taxane From Italian Firm Indena

The new chemical entity has demonstrated activity in taxane-refractory tumors, Spectrum said.

Spectrum Licenses Third-Generation Taxane From Italian Firm Indena

The new chemical entity has demonstrated activity in taxane-refractory tumors, Spectrum said.

GPC Completes Satraplatin Rolling NDA

Company is requesting priority review for use of the novel oral platinum drug in second-line hormone refractory prostate cancer.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel